Therapeutic Solutions International Reports Inhibition of Microglial Activation with NeuroStilbene
January 08 2020 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International
Reports Inhibition of Microglial
Activation with NeuroStilbene
Recent Data Supports NeuroStilbene
to Suppress Neural Inflammation, Induce Regeneration,
and Protect Brain Cells from Death
OCEANSIDE, CA --
January 8, 2020 -- InvestorsHub NewsWire
-- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) reported today
positive animal and human brain cell data demonstrating inhibition
in microglial activation of IL-1 beta, IL-6, and
TNF-a. NeuroStilbene was
also shown to induce neurogenic
growth factors and protected from peroxide and kainic-acid induced
apoptosis.
NeuroStilbene is a
diluted preparation of NanoStilbene and will soon be available from
WCTE, Inc. whom we have recently engaged in a
multi-million-dollar
sales
agreement. NanoStilbene is a Patented and highly concentrated
nanoemulsion of nanoparticle pterostilbene, the active ingredient
contained in both formulations.
Chronic Traumatic
Encephalopathy (CTE) is caused by repetitive
concussive/sub-concussive hits to the head sustained over a period
of years and is often found in football players. The condition is
characterized by memory loss, impulsive/erratic behavior, impaired
judgment, aggression, depression, and dementia. In many patients
with CTE, it is anatomically characterized by brain atrophy,
reduced mass of frontal and temporal cortices, and medial temporal
lobe.
"This is very exciting
data to see that NeuroStilbene
administration in both animals and
human cell lines
preserves
and stimulates
the
proliferation
of endogenous
neural
stem
cells
under
inflammatory
conditions,
while stimulating
neurogenic
growth
factors: BDNF, NGF,
FGF-1, FGF-2. To determine this,
microglial were cultured with TNF-alpha to induce neurogenic growth
factors for 48 hours in the presence of increasing concentrations
of NeuroStilbene" said Dr. Thomas E.
Ichim, Director.
"This data is
phenomenal,
and our
Science Team is currently authoring the manuscript to be submitted
for peer review as quickly as they can. We have now shown in these
experiments that NeuroStilbene
suppresses brain
inflammation,
protects brain
neurons
from death, stimulates the
production of
regenerative factors from microglial, and enhances the
proliferation of endogenous brain stem cells at the same time at
very low dosage" said
Timothy
G. Dixon, President, and CEO.
"We
continue to advance the cause of solving the CTE crisis while
maximizing the potential of this little molecule pterostilbene that
continues to deliver, welcome to 2020."
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is at
www.therapeuticsolutionsint.com
and our
e-commerce is at www.youcanordernow.com and for additional
info on NanoStilbene visit www.mynanostilbene.com.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
Safe
Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information:
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024